Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08 mars 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
22 févr. 2024 16h05 HE
|
Athira Pharma, Inc.
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
08 févr. 2024 16h02 HE
|
Athira Pharma, Inc.
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
08 janv. 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
03 janv. 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
12 déc. 2023 07h00 HE
|
Athira Pharma, Inc.
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative...
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
29 nov. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
28 nov. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
15 nov. 2023 08h15 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
09 nov. 2023 16h05 HE
|
Athira Pharma, Inc.
Continues to report clinical and preclinical findings supporting the potential benefits of its small molecule therapeutic candidates targeting the neurotrophic HGF system as potential novel treatments...